Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 15/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3294838 | 0.85 | ESR2 (0.52) | GHSRPTPN1NR1H2ESR2NPC1 | |
| SCHEMBL3607676 | 0.83 | GHSR (0.49) | GHSRPTPN1NR1H2ESR2NPC1 | |
| SCHEMBL3601158 | 0.83 | GHSR (0.43) | GHSRPTPN1NR1H2ESR2NPC1 | |
| SCHEMBL3607395 | 0.82 | DRD2 (0.46) | GHSRPTPN1NR1H2ESR2 | |
| SCHEMBL25142645 | 0.82 | GHSR (0.47) | GHSR | |
| SCHEMBL3609833 | 0.81 | GHSR (0.49) | GHSRPTPN1NR1H2ESR2 | |
| SCHEMBL3072722 | 0.79 | GHSR (0.62) | GHSR | |
| SCHEMBL14863068 | 0.79 | ESR2 (0.52) | GHSRESR2 | |
| SCHEMBL3075924 | 0.79 | ESR2 (0.52) | GHSRESR2 | |
| SCHEMBL3056292 | 0.79 | ESR2 (0.52) | GHSRESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2010-01-28 | — | — | US | disclosed |
| EP-1857444-A1 | TETRAHYDROISOQUINOLINE COMPOUND AND MEDICINAL USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2007-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | ACAT1, ACAT2, LCAT | GHSR 4556/4885PTPN1 1728/4885NR1H2 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.